What are the unmet needs in AL amyloidosis in Europe?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Efstathios Kastritis, National and Kapodistrian University of Athens, Athens, GR. We asked, What are the unmet needs in AL amyloidosis in Europe? AL amyloidosis is a rare disease caused by the accumulation of amyloid fibers in tissues and organs. In this podcast, Kastritis outlines the need for a more accurate and earlier diagnosis of AL amyloidosis. Kastritis then discusses the need for new therapeutic strategies in patients with advanced (stage IIIb) AL amyloidosis. Finally, he mentions the need for optimized treatment in patients who relapse. Hosted on Acast. See acast.com/privacy for more information.

Om Podcasten

Guided by an international Steering Committee of world experts in Multiple Myeloma (MM), the MM Hub is a global online resource providing key information on Multiple Myeloma for hematologists, oncologists and researchers, run in collaboration with the European School of Haematology (ESH). Our mission is to provide the latest global up-to-date clinical guidance in Multiple Myeloma, through a comprehensive coverage of evidence-based literature, drug approvals, case studies, expert opinions and international congress reports. Hosted on Acast. See acast.com/privacy for more information.